Kathryn Wengel Sells Shares of Johnson & Johnson $JNJ

Key Points

  • Kathryn Wengel sold 10,000 shares of Johnson & Johnson ($JNJ) worth $2.41 million.
  • $JNJ last traded around $240.87.

Kathryn Wengel, EVP, Chief TO and Risk Officer at Johnson & Johnson ($JNJ), sold 10,000 shares at an average price of $241.15, for a total transaction of $2.41 million. The trade was disclosed in a Form 4 filing with the Securities and Exchange Commission.

Johnson & Johnson ($JNJ) Stock

Last price$240.87
Market cap$579.83B
P/E ratio27.94
Forward P/E18.94
PEG ratio3.13
Beta0.26
52-week low$149.04
52-week high$251.71
50-day MA$230.97
200-day MA$214.60
Current ratio1.02
Quick ratio0.69
Debt-to-equity0.68

Johnson & Johnson Earnings

EPS (ttm)$8.62
Revenue (ttm)$96.36B
Revenue growth9.9%
Net margin21.8%
Return on equity26.4%
Next earningsJul 15, 2026

Johnson & Johnson Dividend

Annual dividend$5.36
Dividend yield223.00%
Payout ratio60.2%
Ex-dividend dateMay 26, 2026

Analysts Set New Price Targets

ConsensusBuy
Average target$252.87
High target$285.00
Low target$155.00
Analysts covering23

About Johnson & Johnson

Johnson & Johnson, together with its subsidiaries, engages in the research and development, manufacture, and sale of a range of products in the healthcare field worldwide. It operates in two segments, Innovative Medicine and MedTech. The Innovative Medicine segment offers products for various therapeutic areas, such as oncology, immunology, neuroscience, pulmonary hypertension, infectious diseases, and cardiovascular and metabolism distributed through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. The MedTech segment provides a portfolio of products used in the surgery, orthopedic, cardiovascular, and vision fields distributed through wholesalers, hospitals and retailers, and used in the professional fields by physicians, nurses, hospitals, eye care professionals and clinics. This segment also offers products and enabling technologies that support joint reconstruction, trauma, spine, sports related injuries, and others, as well as open, laparoscopic, and robotic surgical procedures; instrumentation, energy devices, stapling systems, wound closure, biosurgery products, and digital and robotic technologies; breast aesthetics and reconstruction; contact lenses under the ACUVUE brand; intraocular lenses for cataract surgery, and other products used in cataract and refractive procedures under the TECNIS brand. The company was founded in 1886 and is based in New Brunswick, New Jersey.

ExchangeNYSE
SectorHealthcare
IndustryDrug Manufacturers - General
HeadquartersNew Brunswick, NJ
CEOMr. Joaquin Duato
Employees138,200

See Also

This instant news alert was generated by automated narrative technology and financial data from Trueearnings and public regulatory filings. It is for informational purposes only and is not financial advice.